Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hypoxia 4Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Immune System Diseases 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 8fludarabine phosphate 6fludarabine 5Bendamustine Hydrochloride 4Busulfan 3AP 1903 reagent 3pembrolizumab 2Tacrolimus 2Mycophenolic Acid 2thymoglobulin 1pimonidazole 1palbociclib 1ibritumomab tiuxetan 1Valsartan 1Telemedicine 1Surveys and Questionnaires 1Rivaroxaban 1Rituximab 1Radiotherapy 1Plasmalyte A 1Pharmacogenomic Testing 1Melphalan 1Hydroxychloroquine 1Etoposide 1Dimethyl Sulfoxide 1Cytarabine 1Carmustine 1Bone Marrow Transplantation 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immune System Diseases × pimonidazole × Clear all
NCT04658303 2025-05-08

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

University of Pittsburgh

Recruiting
20 enrolled
Dermatologic

Immune System Diseases, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡